These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 25486409)

  • 41. EGFR-TKI-induced HSP70 degradation and BER suppression facilitate the occurrence of the EGFR T790 M resistant mutation in lung cancer cells.
    Cao X; Zhou Y; Sun H; Xu M; Bi X; Zhao Z; Shen B; Wan F; Hong Z; Lan L; Luo L; Guo Z; Yin Z
    Cancer Lett; 2018 Jun; 424():84-96. PubMed ID: 29524558
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation.
    Leung EL; Fan XX; Wong MP; Jiang ZH; Liu ZQ; Yao XJ; Lu LL; Zhou YL; Yau LF; Tin VP; Liu L
    Antioxid Redox Signal; 2016 Feb; 24(5):263-79. PubMed ID: 26528827
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing.
    Park MY; Jung MH; Eo EY; Kim S; Lee SH; Lee YJ; Park JS; Cho YJ; Chung JH; Kim CH; Yoon HI; Lee JH; Lee CT
    Oncotarget; 2017 May; 8(22):36331-36338. PubMed ID: 28422737
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells.
    Jia Z; Zhang Y; Yan A; Wang M; Han Q; Wang K; Wang J; Qiao C; Pan Z; Chen C; Hu D; Ding X
    Cell Death Dis; 2020 Aug; 11(8):670. PubMed ID: 32820157
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early emergence of de novo EGFR T790M gatekeeper mutations during erlotinib treatment in PC9 non-small cell lung cancer cells.
    Kim S; Park AK; Cho J
    Biochem Biophys Res Commun; 2018 Sep; 503(2):710-714. PubMed ID: 29909007
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy.
    Moreira-Leite FF; Harrison LR; Mironov A; Roberts RA; Dive C
    J Thorac Oncol; 2010 Jun; 5(6):765-77. PubMed ID: 20421816
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gefitinib, an EGFR tyrosine kinase inhibitor, activates autophagy through AMPK in human lung cancer cells.
    Xu Z; Hang J; Hu J; Gao B
    J BUON; 2014; 19(2):466-73. PubMed ID: 24965408
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor.
    Rong X; Liang Y; Han Q; Zhao Y; Jiang G; Zhang X; Lin X; Liu Y; Zhang Y; Han X; Zhang M; Luo Y; Li P; Wei L; Yan T; Wang E
    J Thorac Oncol; 2019 Oct; 14(10):1766-1783. PubMed ID: 31228625
    [TBL] [Abstract][Full Text] [Related]  

  • 49. T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non-Small Cell Lung Cancer.
    Watanabe S; Yoshida T; Kawakami H; Takegawa N; Tanizaki J; Hayashi H; Takeda M; Yonesaka K; Tsurutani J; Nakagawa K
    Mol Cancer Ther; 2017 Nov; 16(11):2563-2571. PubMed ID: 28839001
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy.
    To KKW; Wu WKK; Loong HHF
    Eur J Pharmacol; 2018 Mar; 823():19-26. PubMed ID: 29378193
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.
    Zhou J; Hu Q; Zhang X; Zheng J; Xie B; Xu Z; Zhang W
    Oncol Rep; 2018 Apr; 39(4):1783-1792. PubMed ID: 29393480
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumor-Targeted Nanoparticles Deliver a Vitamin D-Based Drug Payload for the Treatment of EGFR Tyrosine Kinase Inhibitor-Resistant Lung Cancer.
    Liu C; Shaurova T; Shoemaker S; Petkovich M; Hershberger PA; Wu Y
    Mol Pharm; 2018 Aug; 15(8):3216-3226. PubMed ID: 29902012
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway.
    Ni J; Zhou LL; Ding L; Zhao X; Cao H; Fan F; Li H; Lou R; Du Y; Dong S; Liu S; Wang Z; Ma R; Wu J; Feng J
    Exp Cell Res; 2017 Dec; 361(2):246-256. PubMed ID: 29080795
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors.
    Choi YJ; Park GM; Rho JK; Kim SY; So GS; Kim HR; Choi CM; Lee JC
    PLoS One; 2013; 8(12):e81393. PubMed ID: 24339922
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
    Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
    Costa DB; Nguyen KS; Cho BC; Sequist LV; Jackman DM; Riely GJ; Yeap BY; Halmos B; Kim JH; Jänne PA; Huberman MS; Pao W; Tenen DG; Kobayashi S
    Clin Cancer Res; 2008 Nov; 14(21):7060-7. PubMed ID: 18981003
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor.
    Kim Y; Ko J; Cui Z; Abolhoda A; Ahn JS; Ou SH; Ahn MJ; Park K
    Mol Cancer Ther; 2012 Mar; 11(3):784-91. PubMed ID: 22228822
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation.
    Lee Y; Choi YR; Kim KY; Shin DH
    Oncotarget; 2016 Jul; 7(28):43315-43323. PubMed ID: 27270313
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
    Yang Z; Zhang SL; Hu X; Tam KY
    Eur J Pharmacol; 2018 Nov; 838():41-52. PubMed ID: 30213498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.